睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07768943,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed extranodal NK/T-cell lymphoma, nasal type, according to the 2022 World Health Organization classification.

    入选标准第 2 条

  3. Lugano 2014 stage IE or IIE disease with a primary site in the upper aerodigestive tract, including but not limited to the nasal cavity, paranasal sinuses, nasopharynx, oropharynx, or oral cavity.

    入选标准第 4 条

  4. Another active malignancy within the previous 6 months requiring surgery, radiotherapy, or systemic anticancer therapy.

    排除标准第 14 条

  5. Eastern Cooperative Oncology Group performance status of 0 to 2.

    入选标准第 7 条

  6. Absolute neutrophil count at least 1.0 x 10\^9/L.

    入选标准第 9 条

    Platelet count at least 75 x 10\^9/L.

    入选标准第 10 条

    Hemoglobin at least 90 g/L.

    入选标准第 11 条

    No granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 14 days before enrollment.

    入选标准第 12 条

    Total bilirubin no greater than 1.5 times the upper limit of normal.

    入选标准第 13 条

    Serum creatinine no greater than 1.5 times the upper limit of normal.

    入选标准第 15 条

  7. Human immunodeficiency virus infection, active hepatitis C virus infection, or hepatitis B virus infection with HBV DNA greater than 10\^3/mL.

    排除标准第 5 条

  8. Pregnancy or breastfeeding.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07768943,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18 to 75 years, inclusive.
  2. Histologically confirmed extranodal NK/T-cell lymphoma, nasal type, according to the 2022 World Health Organization classification.
  3. Diagnosis confirmed by institutional or central pathological review. Tumor tissue must be adequate for morphological assessment, immunohistochemistry, and Epstein-Barr virus-encoded RNA in situ hybridization.
  4. Lugano 2014 stage IE or IIE disease with a primary site in the upper aerodigestive tract, including but not limited to the nasal cavity, paranasal sinuses, nasopharynx, oropharynx, or oral cavity.
  5. At least one disease lesion evaluable by PET/CT at baseline.
  6. No previous chemotherapy, radiotherapy, immunotherapy, or other antitumor biological therapy for lymphoma.
  7. Eastern Cooperative Oncology Group performance status of 0 to 2.
  8. Adequate organ function, including:
  9. Absolute neutrophil count at least 1.0 x 10\^9/L.
  10. Platelet count at least 75 x 10\^9/L.
  11. Hemoglobin at least 90 g/L.
  12. No granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 14 days before enrollment.
  13. Total bilirubin no greater than 1.5 times the upper limit of normal.
  14. Alanine aminotransferase and aspartate aminotransferase no greater than 2 times the upper limit of normal.
  15. Serum creatinine no greater than 1.5 times the upper limit of normal.
  16. Fibrinogen at least 1.5 g/L.
  17. Left ventricular ejection fraction at least 50%.
  18. Ability to understand the study and provide written informed consent.
  19. Willingness to comply with protocol treatment, follow-up, laboratory testing, imaging assessments, and biospecimen collection.

排除标准:Exclusion Criteria:

  1. Diagnosis not meeting the 2022 World Health Organization criteria for extranodal NK/T-cell lymphoma or not confirmed after pathological review.
  2. Lugano stage III or IV disease or distant organ involvement inconsistent with localized early-stage disease.
  3. Primary disease outside the upper aerodigestive tract or predominantly systemic or widespread extranodal disease.
  4. Previous lymphoma-directed chemotherapy, radiotherapy, immunotherapy, or other systemic antitumor treatment.
  5. Human immunodeficiency virus infection, active hepatitis C virus infection, or hepatitis B virus infection with HBV DNA greater than 10\^3/mL.
  6. History of pancreatitis or pancreatic disease considered unsuitable for pegaspargase treatment.
  7. Acute or systemic infection requiring intravenous anti-infective treatment.
  8. Severe complications including hemophagocytic lymphohistiocytosis or disseminated intravascular coagulation.
  9. Significant organ dysfunction, including respiratory failure, chronic congestive heart failure of New York Heart Association class II or higher, decompensated hepatic or renal dysfunction, uncontrolled hypertension or diabetes despite appropriate treatment, or cardiovascular or cerebrovascular thrombosis or bleeding within the previous 6 months.
  10. Active autoimmune disease or another condition considered by the investigator to make immune checkpoint inhibitor treatment unsuitable.
  11. Pregnancy or breastfeeding.
  12. Participants of reproductive potential who are unwilling to use adequate contraception.
  13. Known severe hypersensitivity to any study drug or its excipients.
  14. Another active malignancy within the previous 6 months requiring surgery, radiotherapy, or systemic anticancer therapy.
  15. Severe psychiatric disorder, poor adherence, or another condition that, in the investigator's judgment, would prevent completion of protocol treatment or follow-up.
  16. Current use of another investigational drug or participation in another interventional clinical trial within 4 weeks before enrollment.

引自 ClinicalTrials.gov, NCT07768943, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07768943,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07768943